An effective tumor vaccine is required to induce antigen-specific responses that are able to overcome tumor-mediated immune suppression. Dendritic cells (DCs) play a critical role in the initiation and maintenance of immune response and are regulated by stimulatory as well as inhibitory signaling. Our recent studies demonstrate that the antigen presentation capacity of DCs and the magnitude of adaptive immunity are critically controlled by the suppressor of cytokine signaling 1 (SOCS1) in DCs, and SOCS1-silenced DCs are hyperactivated and have an enhanced immunostimulatory capacity to induce antigen- specific CTL responses. The goal of this study is to develop a novel immunization strategy to overcome tumor-mediated immunosuppression by inhibiting a cytokine signaling inhibitor in DCs. The central hypothesis of this study is that silencing SOCS1 allows unbridled pro-inflammatory STATs signaling to antagonize anti-inflammatory STATS signaling in DCs, leading to the overcoming of tumor-mediated immune suppression and induction of effective antitumor responses.
The specific aims of this study are:
Aim 1). To test the hypothesis that SOCS1 silencing in DCs will allow unbridled pro-inflammatory STATs signaling to antagonize tumor-derived factors-mediated anti-inflammatory STAT3 signaling, leading to the overcoming of tumor-mediated immune suppression and induction of effective antitumor responses.
Aim 2). To test the hypothesis that self-reactive CTLs that are persistently activated by SOCS1-silenced, hyperactivated DCs in tumor-bearing mice are resistant to tumor immunosuppression.
Aim 3). To test the hypothesis that SOCS1-silenced, hyperactivated DCs in the tumor environment can induce a long- term CTL response against self TRP2. The significance of this study is twofold: first, this study will lead to the development of novel tumor vaccines capable of overcoming tumor-mediated immunosuppression and breaking self tolerance by disabling signaling inhibitors such as SOCS1 in DCs; and second, this study contributes to elucidating the mechanisms that regulate T-cell activation and antigen-presentation by DCs in the tumor environment. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116677-02
Application #
7259510
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Howcroft, Thomas K
Project Start
2006-07-12
Project End
2007-08-01
Budget Start
2007-06-01
Budget End
2007-08-01
Support Year
2
Fiscal Year
2007
Total Cost
$112,785
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Jiang, Xiao-Xia; Chou, YuChia; Jones, Lindsey et al. (2015) Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1. Sci Rep 5:13755
Won, Haejung; Nandakumar, Vijayalakshmi; Yates, Peter et al. (2014) Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1. Blood 124:2647-56
Wang, Tao; Nandakumar, Vijayalakshmi; Jiang, Xiao-Xia et al. (2013) The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood 122:2812-22
Nandakumar, Vijayalakshmi; Chou, Yuchia; Zang, Linda et al. (2013) Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1. Proc Natl Acad Sci U S A 110:E3927-36
Hong, B; Peng, G; Berry, L et al. (2012) Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Ther 19:818-27
Song, Xiao-Tong; Turnis, Meghan E; Zhou, Xiaoou et al. (2011) A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther 19:211-7
Jiang, Xiao-Xia; Nguyen, Quan; Chou, YuChia et al. (2011) Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity 35:883-96
Hong, Bangxing; Song, Xiao-Tong; Rollins, Lisa et al. (2011) Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest 121:739-51
Lapteva, Natalia; Aldrich, Melissa; Weksberg, David et al. (2009) Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 32:145-56
Sharabi, Andrew B; Lee, Sung-Hyung; Goodell, Margaret A et al. (2009) Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells 11:523-33

Showing the most recent 10 out of 15 publications